Positive Phase 2 Data: SPY001 Achieves Primary Endpoint in Ulcerative Colitis Trial, Shows Best-in-Class Potential
SYRE has more than doubled off its 52-week low of $10.91.
Summary
Spyre Therapeutics announced highly positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY001 in moderate-to-severe ulcerative colitis. SPY001 met its primary endpoint with a statistically significant reduction in the Robart's Histopathology Index (RHI) score (p<0.0001) and demonstrated clinically meaningful secondary endpoints, including 40% clinical remission and 51% endoscopic improvement, with a well-tolerated safety profile. This news represents a significant advancement in the company's clinical pipeline, building on the Phase 2 timelines highlighted in its recent 10-K. The strong efficacy and safety profile, coupled with the potential for a 'best-in-class' designation, are highly material for Spyre, a clinical-stage biotech, and could significantly de-risk the asset and drive investor confidence. Traders will now monitor the ongoing enrollment for Part B of the SKYLINE trial and anticipate future data readouts for SPY002 and SPY003 in mid-2026 and Q3 2026, respectively, with Part B induction data expected in 2027.
At the time of this announcement, SYRE was trading at $51.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4B. The 52-week trading range was $10.91 to $54.39. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.